Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gembrax Followed by Folfirinox Versus Folfirinox Alone in First-Line Metastatic Pancreatic Cancer
2023-508594-84-00Phase 2Authorised
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Jan 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of nab-paclitaxel, gemcitabine and FOLFIRINOX in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Institut du Cancer de Montpellier. Planned start Jan 2022; status: authorised.
02
Drugs
nab-paclitaxelgemcitabineFOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-508594-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508594-84-00.